BOSTON--(BUSINESS WIRE)--April 4, 2006--Point Therapeutics, Inc. (NASDAQ: POTP - News) presented today new preclinical data in mice indicating that talabostat's effect on the innate immune system correlated with tumor suppression and rejection. These data were presented at the American Association of Cancer Research Annual Meeting (AACR) in Washington D.C. and showed a significant increase in the infiltration of tumor-fighting neutrophils, which are part of the innate immune system. At day 60, the neutrophil-infiltrated tumors in the mice studied were significantly reduced by 79% (where P is less than 0.00005) in size.
